Methods of detecting progesterone receptor and of detecting an expression level

Abstract

A method that includes testing for the presence of a phosphorylated Ser294 (phospho-Ser294) progesterone receptor (PR). A method that includes determining the expression level of a gene in a patient sample and comparing it to a control sample.

1 - 7 . (canceled) 
     
     
         8 . A method comprising:
 determining at least one expression sample level of at least one gene comprising PGR, PAX2, AHR, AR, IRS-1, RUNX, and/or a RUNX-regulated gene, or any combination thereof, in a cell of a biological sample from a patient; and   comparing the at least one expression sample level in a cell of the biological sample to at least one expression level of the at least one gene in a cell of a control sample.   
     
     
         9 . The method of  claim 8 , the method further comprising determining if the expression sample level of the at least one gene is decreased as compared to the control sample. 
     
     
         10 . The method of  claim 9 , wherein the at least one gene further comprises a gene selected from the genes listed in Table 5B, Table 6B, Table 7B, Table 8B, Table 9B, or Table 10B. 
     
     
         11 . The method of  claim 8 , the method further comprising determining if the expression sample level of the at least one gene is increased as compared to the control sample. 
     
     
         12 . The method of  claim 11 , wherein the at least one gene further comprises a gene selected from the genes listed in Table 4, Table 5A, Table 6A, Table 7A, Table 8A, Table 9A, or Table 10A. 
     
     
         13 . The method of  claim 8 , wherein a RUNX-regulated gene comprises a gene selected from the genes listed Table 9. 
     
     
         14 . A method comprising:
 determining at least one expression sample level of at least one gene comprising a gene selected from the genes listed in Tables 4-10, or any combination thereof, in a cell of a biological sample from a patient; and   comparing the at least one expression sample level in a cell of the biological sample to at least one expression level of the at least one gene in a cell of a control sample.   
     
     
         15 . The method of  claim 14 , wherein comparing the at least one expression sample comprises determining if the expression sample level of at least one gene selected from the genes listed in Table 5B, Table 6B, Table 7B, Table 8B, Table 9B, and Table 10B is decreased as compared to the control sample. 
     
     
         16 . The method of  claim 14 , wherein comparing the at least one expression sample comprises determining if the expression sample level of at least one gene selected from the genes listed in Table 4, Table 5A, Table 6A, Table 7A, Table 8A, Table 9A, and Table 10A is increased as compared to the control sample. 
     
     
         17 . The method of  claim 8 , the method further comprising administering a therapeutically effective amount of a PR antagonist to the patient. 
     
     
         18 . The method of  claim 14 , the method further comprising administering a therapeutically effective amount of a PR antagonist to the patient. 
     
     
         19 . The method of  claim 17 , wherein the PR antagonist comprises at least one of onapristone, mifepristone, aglepristone, and WAY-348. 
     
     
         20 . The method of  claim 18 , wherein the PR antagonist comprises at least one of onapristone, mifepristone, aglepristone, and WAY-348.